welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

82% Informative

Pfizer Inc. ( NYSE : PFE ) recently announced entering into an exclusive licensing agreement with 3SBio , a leading Chinese biopharmaceutical company.

The agreement entails the development, manufacturing, and commercialization of SSGJ-707, which is a bispecific antibody targeting PD-1 and VEGF .

The drug is currently under clinical trials in China for treating non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

VR Score

83

Informative language

83

Neutral language

35

Article tone

formal

Language

English

Language complexity

68

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links